Senzime: Sensors Sprinting, Monitors Still Stuck in Purchasing

A 74% gross margin and a near-breakeven September are real — but the U.S. monitor excuse is now a three-quarter refrain, and TetraGraph-as-a-Service quietly went to zero

SEZI.ST · Earnings Call · 2026-10-29

The P&L finally started behaving

For a company that has spent years selling a story about clinical conversion, Senzime's Q3 was unusual: the arithmetic caught up with the narrative. Revenue of SEK 30.1 million, “We reported growth in all our regions around the world. We regained growth and grew 14%.” — Philip Siberg, CEO · 2026-10-29 The mix is the point — disposable sensor sales grew 43% and reached 83% of the business, while monitors dragged. That is roughly the right direction for a razor-and-blade model: the installed base compounds, and the consumables do the compounding. Gross margin hit 74%, up 13 points year over year, helped by the sensor-heavy mix, redesigned disposables with European-based production, and a small tariff repayment. Management was careful to strip that out: “I would say that the normalized gross margin level is probably 71%, 72%” — Philip Siberg, CEO · 2026-10-29 — still a structural step up from the low 60s. OpEx fell 15%, EBITDA improved to minus SEK 8 million from minus SEK 19.4 million, and the cash burn narrowed to SEK 8.7 million from SEK 28.3 million. September was, in the CEO's words, almost breakeven. Liquidity: SEK 28.7 million of cash plus a refinanced SEK 35 million credit line from the Segulah and Crawford vehicles, roughly SEK 63.7 million available. For a company with a market cap around USD 56 million, that is not generous — it is adequate, and only adequate.

The alibi that keeps reappearing

Here is where the story bends. Monitor sales have now been explained away in three consecutive calls with near-identical language. In February, the Q4 miss was a "tricky" U.S. December. In April, Q1 was "an outlier" and the CEO was confident: “I feel that the market is kind of waking up.” — Philip Siberg, CEO · 2026-04-22 Asked if he still expected a bounce-back, he said “I do. I do. Yes.” — Philip Siberg, CEO · 2026-04-22 Three weeks into April. Q2 then produced the TetraGraph-as-a-Service launch, with “We won a number of these deals.” — Philip Siberg, CEO · 2026-02-20 Now Q3: “It takes longer time to close the deals. Deals can get approved. They continue to get stuck with purchasing, with legal.” — Philip Siberg, CEO · 2026-10-29 The pipeline is again described as strong and again described as uncontrollable in timing — “We have a strong pipeline. It's just a controllable of when is it happening.” — Philip Siberg, CEO · 2026-10-29 That is candid, but it is also the same sentence with a different quarter attached. The monitor sales line has become the company's recurring disappointment, and investors have now been told twice that a catch-up effect was imminent and got one quarter of it at best.

We've had about 800 hospitals we now have worldwide, many of them were early adopters, technology freaks, drivers of we want to be guideline compliant... And now we're probably a little bit at the chasm where we're reaching the mass market. So some of these budgets to get these more big mass market hospitals may take a little bit longer time.
Philip Siberg, CEO · 2026-10-29

That is the most honest thing said on the call, and it is strategically important. The 6,000 systems placed across 800 hospitals in 30 markets sit against a stated opportunity of more than 400,000 operating rooms. The bottleneck is not clinical demand or guideline pressure — it is hospital procurement, legal, and capital budgets. Which is precisely why the business model matters.

The model that vanished from the quarter

Which makes the as-a-service disclosure the strangest moment of the call. The whole point of TetraGraph-as-a-Service, introduced with some fanfare in February, was that it sidesteps the capital-approval queue and shortens the sales cycle materially. It was supposed to be the answer to the exact problem being described three quarters later. And in Q3:

We didn't have any TetraGraph-as-a-Service contracts during Q3. We do have a lot in the pipeline. I think we potentially have underestimated a little bit that we thought that it would go a lot faster because of the -- you don't have to buy the capital, but just the legals of the documentation and the framework agreement still takes some time.
Philip Siberg, CEO · 2026-10-29

Zero contracts in the quarter. The mechanism designed to bypass the purchasing logjam is now itself stuck in legal documentation — a framework agreement problem instead of a capital-budget problem. Management says Q4 pipeline exists and that the few running deployments (a couple of Ivy League hospitals) show favorable unit economics. But the read-through is that the accelerated path is not yet accelerated, and the positive cash flow target now leans on ordinary monitor closings arriving in November and December.

The one genuinely market-wide tailwind

Curiously, the freshest cross-market theme in this report is the smallest number in it. Senzime booked a USD 116,000 U.S. tariff repayment in the quarter, with roughly USD 260,000 more expected — "they're favorizing the big ones and smaller ones are second in line," the CEO noted. That is a rounding error for Senzime, but it is a direct hit on one of the dominant global themes of the last two quarters: Tariff refund topped the whole-market keyword table in Q2 2026, and net tariff refunds remained a top-five market theme in Q3, with a long list of reporters — coatings, packaging, steel, distributors — all booking IEEPA refunds. Senzime is a micro-cap riding a macro refund wave it did not create, and management is explicitly normalizing the margin for it. That is the right instinct. Elsewhere the company is riding a more durable, if slower, wave: guideline adoption, particularly European pediatric standards requiring EMG-based monitoring, which visibly bent the pediatric growth curve. And the utilization rate KPI — sensors used per monitor per week — is up about 60% this year in U.S. key accounts, with the University of Miami case at roughly 80%. That is the single best argument that the installed base is monetizing rather than gathering dust.

What to hold the story to

The Philips OEM partnership — Philips, the largest deal in company history — got the standard treatment: progressing as planned, nothing to disclose on timing, and a view that more than half of the business could be OEM-driven over ten years. Fine, but unverifiable. The May 2025 U.S. Veterans Affairs sole-source framework — 170-plus hospitals — has "a couple" of VAs as customers. That is the same slow-burn pattern. So the checklist is narrow. Positive cash flow inside Q4 (meaning November or December) has been promised since at least February and reiterated in April; a third reiteration without delivery would be a credibility event, not a timing event. Second, at least one as-a-service contract closing in Q4. Third, monitor revenue turning positive to validate the "catch-up" thesis rather than restating it. Senzime has genuinely fixed the part of the model it controls — cost, mix, gross margin, working capital. What it has not yet proven is that it can convert a 400,000-operating-room opportunity into contracts at a pace its balance sheet can fund. The sensors are doing the talking; the monitors need to start.